Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 4/20 | 0.52 |
| ▸ | CNR2 | P34972 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.43 |
| ▸ | FAAH | O00519 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL675634 | 1.00 | CNR1 (0.52) | CNR1CNR2MAPTTP53EPHX2 | |
| SCHEMBL3725521 | 0.86 | CNR1 (0.52) | CNR1CNR2MAPTTP53EPHX2 | |
| SCHEMBL3725522 | 0.86 | CNR1 (0.52) | CNR1CNR2MAPTTP53EPHX2 | |
| SCHEMBL3720222 | 0.85 | MAPT (0.46) | CNR1CNR2MAPTTP53MEN1 | |
| SCHEMBL676231 | 0.84 | CNR1 (0.51) | CNR1CNR2MAPTTP53EPHX2 | |
| SCHEMBL676230 | 0.84 | CNR1 (0.51) | CNR1CNR2MAPTTP53EPHX2 | |
| SCHEMBL676502 | 0.83 | LTB4R (0.43) | CNR1CNR2MAPTTP53MEN1 | |
| SCHEMBL676501 | 0.83 | LTB4R (0.43) | CNR1CNR2MAPTTP53MEN1 | |
| SCHEMBL675870 | 0.81 | MEN1 (0.49) | MAPTTP53MEN1KMT2APOLB | |
| SCHEMBL3724384 | 0.81 | MEN1 (0.43) | CNR1CNR2MAPTTP53MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895744-B2 | Alfa-carboline inhibitors of NPM-ALK, RET, and Bcr-Abl | UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA (IT) | 2014-11-25 | — | — | US | disclosed |
| US-20110281862-A1 | ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL | UNIVERSITA' DEGLI STUDI DI MILANO - BICOCCA (IT) | 2011-11-17 | — | — | US | disclosed |
| CN-102203092-A | Alfa-carboline inhibitors of npm-alk, ret, and bcr-abl | UNIV DEGLI STUDI MILANO | 2011-09-28 | — | — | CN | disclosed |
| EP-2161271-A1 | Alpha-carboline inhibitors of NMP-ALK, RET, and Bcr-Abl | Università Degli Studi Di Milano - Bicocca (IT) | 2010-03-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281862-A1 | ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL | ALK, BCR, NPM1 | CNR1 442/4885CNR2 965/4885MAPT 1494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.